There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Actinium Pharmaceuticals (NYSE: ATNM), VistaGen Therapeutics (NASDAQ: VTGN) and Corbus Pharmaceuticals (NASDAQ: CRBP) with bullish sentiments.
Actinium Pharmaceuticals (NYSE: ATNM)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $3. The company’s shares closed yesterday at $0.48, close to its 52-week low of $0.33.
McCarthy observed:
“Actinium announced initiation of a Phase 1 study of Actimab-A (Actinium-225 labeled anti CD33 antibody) + salvage chemotherapy (CLAG-M) in relapsed/ refractory acute myeloid leukemia (r/r AML).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.1% and a 45.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Currently, the analyst consensus on Actinium Pharmaceuticals is Strong Buy and the average price target is $3.58, representing a 653.7% upside.
In a report issued on May 29, Oppenheimer also assigned a Buy rating to the stock with a $5 price target.
See today’s analyst top recommended stocks >>
VistaGen Therapeutics (NASDAQ: VTGN)
In a report released yesterday, Jay Olson from Oppenheimer assigned a Buy rating to VistaGen Therapeutics (NASDAQ: VTGN), with a price target of $6. The company’s shares closed yesterday at $1.49.
Olson said:
“The US Office has issued two key patents for VistaGen’s lead asset AV-101. On 12/5/2017, the USPTO granted U.S. Patent No. 9,834,801 related to certain methods of production for AV-101. Office granted a a patent application related to methods of treating depression with AV-101. This patent (US Patent No. 9,993,453) and an additional patent related to oral formulation ( 9,993,450) were issued today. Mgm’t estimates that these patents would not expire until at least 2034 and represent a fundamental milestone. We believe VTGN’s unique antidepressant (AV-101) may offer ketamine-like efficacy without the side effects or inconvenience, and recently initiated coverage* with a $6 price target.”
According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.4% and a 48.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
VistaGen Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.
Corbus Pharmaceuticals (NASDAQ: CRBP)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) yesterday and set a price target of $32. The company’s shares closed yesterday at $6.15.
Piros observed:
“We rate Corbus Pharmaceuticals Overweight. CRBP focuses on the development of a synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum (JBT-101), for the treatment of rare inflammatory and fibrotic diseases. The company has completed three successful Phase 2 clinical trials in patients with cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (dcSSc) and dermatomyositis (DM). Valuation Summary We value Corbus based on a risk-adjusted NPV of future cash flows associated with lenabasum. Our 12-month price target is $32/share.”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.3% and a 51.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Corbus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRBP:
